Publications by authors named "N Pon Saravanan"

In recent years, the design of various ultrasound responsive echogenic nanomaterials offers many advantages such as deep tissue penetration, high signal intensity, colloidal stability, biocompatibility and less expensive for ultrasound-based cancer cell imaging while providing the option to monitor the progress of tumor volume during the treatment. Further, the ability of nanomaterials to combine photo-thermal therapy (PTT) and chemotherapy has opened a new avenue in the development of cancer theranostics for synergistic cancer therapy. Herein, we report MoS nanoflowers (NFs) surface decorated with CuS nanorods (NRs) and folic acid-derived carbon dots (FACDs) using cystine-polyethyleneimine (PEI) linker for PTT-chemotherapy.

View Article and Find Full Text PDF

The Alzheimer's Disease Sequencing Project (ADSP) is a national initiative to understand the genetic architecture of Alzheimer's Disease and Related Dementias (AD/ADRD) by sequencing whole genomes of affected participants and age-matched cognitive controls from diverse populations. The Genome Center for Alzheimer's Disease (GCAD) processed whole-genome sequencing data from 36,361 ADSP participants, including 35,014 genetically unique participants of which 45% are from non-European ancestry, across 17 cohorts in 14 countries in this fourth release (R4). This sequencing effort identified 387 million bi-allelic variants, 42 million short insertions/deletions, and 2.

View Article and Find Full Text PDF

NIAGADS is the National Institute on Aging (NIA) designated national data repository for human genetics research on Alzheimer's Disease and related dementia (ADRD). NIAGADS maintains a high-quality data collection for ADRD genetic/genomic research and supports genetics data production and analysis. NIAGADS hosts whole genome and exome sequence data from the Alzheimer's Disease Sequencing Project (ADSP) and other genotype/phenotype data, encompassing 209,000 samples.

View Article and Find Full Text PDF
Article Synopsis
  • There is a complex difference between autoimmune and alloimmune reactions in liver transplant patients, particularly involving an under-recognized form of graft rejection called plasma cell-rich rejection (PCRR).
  • PCRR can lead to serious complications like advanced liver damage and transplant failure if not treated quickly, highlighting the need for effective detection methods.
  • This study reviews potential blood and tissue biomarkers for diagnosing and monitoring PCRR in liver transplant recipients, as well as discusses related biomarkers from other medical conditions that might be applicable.
View Article and Find Full Text PDF